A screen
                        of apoptosis and senescence regulatory genes for life span effects when












































A number of stresses can cause cells to enter a non-
dividing state called cellular senescence [1].  These 
stresses include repeated cell division, expression of 
activated oncogenes, oxidative stress, and irradiation. 
The cellular senescence pathway functions as an anti-
tumor mechanism in mammals, and is regulated by the 
tumor-suppressor proteins p53 and Rb.  Senescence of 
cells during aging may contribute to mammalian aging 
phenotypes by limiting the ability of stem cell  popula- 
 
 


















































































tions to replenish tissues.  Several Drosophila tissues 
are maintained by dividing stem cell populations, 
including the gonads [2], the gut [3, 4] and the 
malpighian tubule (equivalent to mammalian kidney) 
[5], however it is currently unknown whether alterations 
in these stem cell populations during aging has an effect 
on Drosophila life span.  
 
Apoptosis (programmed cell death) is also implicated in 
mammalian and Drosophila aging phenotypes.   
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in dividing tissues such as the gut and hematopoetic 
system, and abnormal apoptotic events have been 
observed in muscle and other tissues during mammalian 
aging [6].  In addition, apoptosis is implicated in several 
human aging-related diseases, for example 
neurodegenerative diseases such as Alzheimer’s disease 
and Parkinson’s disease [7].  In aging Drosophila, 
abnormal apoptotic events have been observed in 
muscle and fat tissue [8], but the extent to which 
apoptosis (or cellular senescence) might modulate 
Drosophila life span remains largely unknown. Several 
genes that can affect apoptosis (and senescence) have 
been found to affect Drosophila life span, including 
DPOSH,  MnSOD and p53 [9-12]. In mammals 
hyperactive p53 can produce an accelerated-aging-like 
phenotype [13], and in Drosophila a dominant-mutant 
p53 transgene can inhibit insulin-like signaling and 
cause increased life span [14]. However, the extent to 
which these effects on life span might be mediated by 
alterations in apoptosis and/or cellular senescence 
pathways is largely unknown.  The potential importance 
of the cellular senescence and apoptosis pathways in 
modulating life span prompted a screen of additional 
genes implicated in these pathways for life span effects 
in the fly. 
 
Conditional gene expression systems have several 
advantages for studies of aging: for example with the 
Tet-on system the expression of transgenes is triggered 
by feeding the flies the drug doxycycline, and with the 
Geneswitch system transgene expression is triggered 
using the drug RU486/Mifepristone [15-17].  These 
conditional systems allow for transgene expression to 
be limited to specific life cycle stages such as 
development or adulthood.  Moreover, these systems 
provide powerful controls for genetic background 
effects on life span, since the control and gene-over-
expressing animals have identical genetic backgrounds 
and differ only in the presence or absence of the drug.  
It is often desirable to over-express a gene in all the 
tissues of the fly, for example when screening genes for 
possible life span effects.  We have recently reported 
the generation of a Geneswitch system driver (called 
“Act-GS-255B”), which contains multiple inserts of a 
construct in which the promoter of the cytoplasmic actin 
gene  Actin5C is used to drive expression of the 
Geneswitch transcription factor [16].  Here the Act-GS-
255B driver is further characterized using a UAS-GFP 
reporter, and we report that it is truly tissue-general in 
both the larval and adult stages. The tissue-general 
driver facilitated the screening of senescence and 




Characterization of Geneswitch drivers in adult flies 
using the UAS-GFP reporter 
 
To facilitate the screen of apoptosis and senescence-
regulatory genes for life span effects, several 
Geneswitch system drivers were characterized for their 
tissue-specificity of transgene activation using a UAS-
GFP reporter, both in adult flies and during larval 
development.  The UAS-GFP reporter employed was 
“UAS-ultraGFP” which contains multiple copies of a 
UAS-eGFP construct, and yields particularly high levels 
of GFP expression [18].   Three Geneswitch system 
drivers were characterized: The Act-GS-255B driver 
strain contains multiple inserts of a construct in which 
the promoter from the cytoplasmic actin gene Actin 5C 
drives Geneswitch, and is expected to yield tissue-
general expression [16]. The Elav-GS driver contains 
Geneswitch under control of the Elav gene promoter 
and produces nervous-system-specific expression [19].  
Finally the whole-body fat-body Geneswitch driver 
strain (“WB-FB-GS”) contains both a head fat-body 
driver (S1-32) and a body-fat-body driver (S1-106) [20-
22], and is expected to yield expression in the fat-body 
tissue throughout the animal. The three driver strains 
were crossed to the UAS-ultraGFP reporter strain to 
produce adult progeny containing both the driver and 
reporter constructs, and the flies were cultured in the 
presence and absence of drug for two weeks.   GFP 
expression was scored in live adult flies as well as in 
several dissected tissues (Figure 1).  The Act-GS-255B 
driver was found to yield tissue-general expression of 
the UAS-ultraGFP reporter in adult flies.  In whole 
adults, GFP expression was observed throughout the 
body of both males and females, with greater expression 
levels observed in females relative to males.  Similarly 
with heads dissected in half and bodies dissected in half, 
expression was observed in all tissues, including 
abundant expression in nervous system, muscle (inclu-
ding flight muscle), and fat-body tissue.  Note that flight 
muscle in male has lower expression than flight muscle 
in female, however inspection of the GFP-only image 
for male flight muscle (inset) reveals expression 
throughout this tissue.  Abundant expression was also 
observed throughout dissected gut tissue, ovary and 
testes.  The expression level was greater in some re-
gions of the gut than others, however all regions of the 
gut exhibited staining, as revealed by inspection of the 
GFP-only images (inset).  All tissues observed showed 
significant GFP expression, and therefore we conclude 
that Act-GS-255B yields truly tissue-general expression 
in  adult flies.  The  WB-FB-GS  driver produced  GFP 
 
 
   














































expression in the head-fat-body and body-fat-body 
tissues, as expected, as well as in the gut and testes, and 
very faint expression in ovary; there was no detectable 
expression in nervous, muscle, or other tissues.   
Notably, the expression in adult male head fat body was 
much reduced relative to female head fat body, 
consistent with recent characterization of the fat body 

























































GS driver produced  abundant  expression  in  the brain 
and ventral nerve cord, as expected, and there was no 
detectable expression in any other tissues; for example, 
the muscle, gut and gonads were clearly negative. Note 
the GFP-only image for the gut (inset) shows a lack of 
expression.  The Elav-GS driver was found to produce 
similar levels of UAS-GFP reporter expression in male 
versus female in our experiments. 
 
   

















































Characterization of Geneswitch drivers in larvae 
using the UAS-GFP reporter 
   
The Geneswitch driver strains were also scored for 
expression patterns in 3
rd instar larvae and dissected 































































to yield tissue-general expression, including abundant 
expression throughout the body of whole 3
rd instar 
larvae, as well as in dissected brain, gut, salivary gland, 
imaginal discs and fat-body tissues; all tissues observed 
showed abundant GFP expression (Figure 2A).  The 
inset for the Act-GS-255B 3
rd instar larval brain shows 
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expression was present throughout the brain, with higher-
level expression in a subset of cells.  The WB-FB-GS 
driver was found to drive abundant expression in salivary 
gland and anterior midgut, but notably no expression in 
any other larval tissues including larval fat-body.  Finally 
the Elav-GS driver produced abundant expression in 
larval nervous system and no detectable expression in 
any other larval tissues. The inset for the Elav-GS 3
rd 














































and shows that expression was present throughout the 
brain, with higher-level expression in a subset of cells. 
Notably this subset of cells was different from that 
observed above with Act-GS-255B.  Each of the three 
drivers was found to produce similar patterns of 
expression in 1
st and 2
nd  instar larvae as well (Figure 
1B).  When the Act-GS-255B driver was induced using 
dilutions of RU486 drug in the culture media, it produced 
a dose-response of GFP expression in 3
rd instar larvae 

































Figure  3.  Effect  of  transgene  over‐
expression  on  survival  of  adult  flies.
Apoptosis  and  senescence‐related  genes



















   




































Effect of apoptosis and senescence-regulatory gene 
over-expression on life span 
 
Fourteen apoptosis and senescence regulatory genes 
were chosen for analysis based on their relevance to 
human apoptosis and senescence pathways and the 
availability of reagents for Drosophila.  Ras85D is a 
Drosophila homolog of the human oncogene Ras that 






















































Ras85D activated form contains an amino acid 
substitution that causes Ras to be constitutively active 
[23], and Ras85D dominant negative ( DN) form 
contains an amino acid substitution that causes it to 
inhibit the endogenous Ras protein [23, 24].  Wingless 
is a Drosophila homolog of the human Wnt signaling 
protein involved in development and tumorigenesis 
[25].  Pk61C is a serine/threonine protein kinase related 
to human PDK-1 and involved in growth signaling [26].  
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apoptosis protein (IAP) family [27]. Baculovirus p35 is 
a caspase inhibitor protein also related to the IAPs.   
Nemo ( nmo) is the Drosophila homolog of a human 
protein kinase regulatory subunit involved in NF-
kappaB signaling pathway [28].  Egfr is the Drosophila 
homolog of the human epidermal growth factor receptor 
[29]. The Drosophila  pointed ( pnt) gene encodes a 
transcription factor homologous to human Ets1 that is 
involved in the Ras signaling pathway.  The Drosophila 
Matrix metalloproteinase 2 gene (Mmp2) is involved in 
tissue remodeling  and tumor progression and is related 
to a family of human matrix metalloproteinases [30].  
The Drosophila Stat92E gene encodes a homolog of the 
human Stat transcription factor, which is a target of the 
Jak-Stat growth-regulatory pathway [31].  The 
Drosophila puckered (puc) gene encodes a phosphatase 
homologous to the human VH-1 family that antagonizes 
JNK signaling, and heterozygous puc mutant flies have 
been reported to have increased stress resistance and life 
span [32, 33]. The Drosophila  Sphingosine kinase 2 
(Sk2) gene encodes a lipid kinase involved in activation 
of protein kinase C-family signaling, and the human 
homolog Sphk2 is implicated in regulation of apoptosis 
[34].  Finally the CG14544 gene encodes a predicted 
methyltransferase, and the Drosophila  bantam ( ban) 
gene encodes a micro-RNA that inhibits expression of 
pro-apoptotic genes [35]. Each of these genes of interest 
was over-expressed in adult flies or during larval 
development, and assayed for effects on adult fly life 
span. 
 
To control for any possible effects of the Geneswitch 
system and the RU486 drug itself, life span was assayed 
in flies that were the progeny of Act-GS-2555B driver 
crossed to either Oregon-R (Or-R) wild-type strain or to 
the w
1118 control strain, to produce progeny containing 
only the driver.  In these control flies, treatment with 
drug produced small, but statistically significant 
reductions in life span in both male and female adults: 
treatment during adulthood reduced mean life span by -
4% to -10%, while treatment in larval stages reduced 
adult life span by –8% to -16% (Figure 3A, B; Figure 
4A, B; Tables 2, 3).  There were no significant increases 
in life span in control flies treated with RU486 in any of 
the replicate experiments.  These data indicate that in 
these experiments, when the Act-GS-255B driver is 
present, the RU486 can cause small but significant 
reductions in adult life span, and this effect must be 
taken into account when interpreting the effects of 
transgene over-expression. Other studies [22], including 
ones from our own laboratory using the Act-GS-255B 
driver [36], found no negative effects of RU486 on 
adult fly life span. We conclude that the small negative 
effects observed here result from differences in the lot 
of RU486 drug, and/or small differences in effective 
concentrations due to specifics of media preparation. To 
confirm that the Act-GS-255B driver can produce 
increased life span, it was used to drive over-expression 
of the dominant p53 allele (p53-259H).  Over-
expression of p53-259H in adult flies using the 
ubiquitous Act-GS-255B driver produced increased 
median life span in females (+8%) but not males (-
2.8%), and no life span increase when expressed in 
larvae (Table 3). These results are consistent with 
previous studies showing that expression of p53-259H 
in the adult nervous system with the Elav-GS driver can 
cause increased life span in females [14], and confirms 
that the Act-GS-255B driver can indeed produce 
increased life span when combined with an appropriate 
target gene.  
 
Most of the genes tested by over-expression with the 
ubiquitous Act-GS-255B driver did not affect life span 
to an extent greater than the small changes observed 
with the control flies.  However, Ras activated form 
transgene was lethal when expressed in larvae, and 
reduced both male and female life span by –80% when 
expressed in adults (Figure 3C, D; Table 2).  Over-
expression of wild-type Ras or a Ras dominant-negative 
allele was not lethal to larvae, and produced only small 
decreases (-4% to –12%) in both male and female adult 
life span (Figure 2 E, F; Table 2), thereby in the range 
of negative effects observed with control flies.  Over-
expression of the wingless gene was found to be lethal 
to male and female larvae, using two independent 
wingless transgenes (Table 2).  Over-expression of 
wingless in adult flies produced significant reductions in 
both male and female life span: ~-42% with one 
wingless transgene (Figure 3 G, H) and ~-10% with the 
other transgene (Table 2).   
 
Finally, the tissue-general Act-GS-255B driver was 
used to over-express three different transgenes encoding 
the caspase inhibitor Baculovirus p35, during larval 
development and in adult flies (Figure 4; Table 3).   
Over-expression of Baculovirus p35 in adult flies using 
the tissue-general Act-GS-255B driver produced only 
small decreases in life span that were within the range 
observed with control flies, suggesting there were no 
significant effects in adults.  In contrast, when 
Baculovirus p35 was over-expressed during larval 
development using the tissue-general driver, it reduced 
the mean life span of male and female adults by –20% 
to –50%.  Interestingly, over-expression of each of the 
three independent Baculovirus p35 transgenes during 
larval development produced an unusual biphasic-
shaped survival curve in adult females (Figure 4 D, F, 
H), suggesting the presence of a subset of adult female 
flies  with  unchanged  or  even  increased  life  span.  A  
   





























Gompertz-Makeham model was found to give the best 
fit to the life span data for females in which Baculovirus 
p35 was over-expressed during larval development 
(Figure 5; Table 4).  This analysis revealed that the 
decrease in mean life span was due to increased age-
independent mortality. When the age-independent 
mortality was removed and the data re-plotted, it 
revealed a subset of female flies with unchanged 
(Figure 5 B, F) or increased life span (Figure 5D).  
 
Two independent Baculovirus p35 transgenes were also 
over-expressed in adult flies using the head-fat-body 
driver S1-32, and the whole-body fat-body driver (S1-32 
plus S1-106), and during larval development using the 
whole-body fat-body driver, however no consistent 















































The nervous system-specific Elav-GS driver was also 
used to over-express two baculovirus p35 transgenes.   
In adults the Elav-GS driver itself had little to no effect 
on life span, and over-expression of baculovirus p35 in 
adults using Elav-GS had no consistent effects on life 
span (Table 3).  In contrast, when drug was adminis-
tered to larvae, the Elav-GS driver itself was associated 
with significant decreases in life span in both males (~-
30% to –40%) and females (~-25%), and significantly 
reduced the number of male adults, and no effects of the 
baculovirus p35 transgenes on life span could be 
identified in this background (Table 3).  In an attempt to 
reduce this background toxicity and allow assay of 
baculovirus p35 transgenes with the Elav-GS driver in 
larvae, a 1:10 dilution of drug was used.  Under these 
conditions the life span reductions caused by drug in 
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the number of males obtained was approximately 
normal, however no increases in life span were 
observed upon over-expression of baculovirus p35 
(Table 3). 
 
The muscle-specific MHC-GS driver was used to drive 
over-expression of several transgenes in adult flies, 
however the MHC-GS driver itself was found to cause a 
significant RU486-dependent decrease in life span in 
both males and females (~-20% to –30%), and none of 
the target transgenes tested produced a significant life 




The tissue and temporal specificity of transgene 
expression can have significant effects on Drosophila 
life span, and therefore the ability meaningfully to 
interpret results depends upon careful characterization 
of the expression patterns produced by the system 
chosen to drive transgene expression [17, 37].  Here the 
Geneswitch system driver Act-GS-255B was found to 
yield tissue-general expression of target transgenes in 
both larvae and adults, including modulation of 
expression by titrating the concentration of drug in the 
food.  Some sex-dependent effects on expression were 
observed with the Geneswitch drivers.  For example, 
Act-GS-255B produced tissue-general expression in 
both males and females, however females consistently 
exhibited higher levels of expression than males.   
Poirier et al have recently reported that the Geneswitch 
driver S1-106 (head fat body) is active in adult females 
but not males [17], and we found a similar result.   
Poirier et al also reported that the Elav-GS (nervous 
system) driver had a female bias, but in our experiments 
the Elav-GS driver supported similar levels of UAS-
GFP expression in males and females.  It was particu-
larly striking that while the S1-106 and S1-32 drivers 
produced abundant target gene expression in adult fat 
body, they did not support expression in the larval fat 
body.  
 
For the Elav-GS driver, previous studies have reported 
pan-neuronal expression in larvae using a UAS-eGFP 
reporter [19], nervous system-specific expression in 
adults using a UAS-eGFP reporter [16], and expression 
in a subset of neurons in brain and ventral nerve cord in 
adults using a UAS-LacZ reporter [17].  Here, using the 
UAS-ultraGFP reporter, Elav-GS was found to produce 
pan-neuronal staining (i.e., expression in all nervous 
tissue), plus higher-level expression in a subset of 
neurons, in both larvae and adults, whereas no 
expression was observed in any tissues other than 
nervous system in either larvae or adults.  In contrast, 
Poirier et al reported that the Elav-GS driver produced 
staining in the digestive system (gut) when it was tested 
with the UAS-LacZ reporter, and that this signal in gut 
was not induced by drug [17].  One possible explanation 
for this difference in results is that the endogenous 
Drosophila β-galactosidase is expressed in sub-regions 
of the gut [38], and this could have resulted in a 
background signal when staining for transgenic LacZ 
activity.  Alternatively, the expression pattern produced 
by the Elav-GS driver might be affected by culture 
conditions or genetic background differences.  
 
When the Act-GS-255B ubiquitous driver was used to 
drive expression of the p53-259H transgene in adult 
flies, it produced life span extension in females, 
consistent with previous results using the Elav-GS 
driver [9], and therefore demonstrating that the Act-GS-
255B driver can produce increased life span when 
combined with an appropriate target gene.  Of the 
fourteen candidate genes tested by over-expression, 
only a subset caused significant and reproducible effects 
on life span: wingless and Ras activated form caused 
negative effects, while baculovirus p35 produced both 
positive and negative effects depending upon sex and 
developmental stage for over-expression. Care must be 
taken when interpreting negative effects on life span, 
since life span might be decreased due to a novel 
pathology unrelated to the normal mechanisms 
modulating life span.  However, that said, it is 
interesting that these particular genes/pathways were 
identified from among the set of genes tested. 
 
Over-expression of wingless using the tissue-general 
Act-GS-255B driver was lethal to male and female 
larvae, and when expressed in adult flies wingless 
dramatically decreased both male and female life span.  
In  Drosophila,  wingless signaling promotes main-
tenance of the gut stem cells [39, 40] and somatic stem 
cells in the ovary [41]. Interestingly, the wingless 
homolog Wnt and the Wnt signaling pathway have been 
implicated in modulating aging-related cellular 
phenotypes in mammals [42]:  Wnt signaling is impli-
cated in tissue homeostasis and the maintenance of adult 
stem cell populations in younger mammals, while 
conversely Wnt signaling is implicated in promoting 
senescence of muscle stem cells in aging mammals [43]  
Moreover, the Klotho gene appears to function by 
inhibiting Wnt signaling, and Klotho mutation produces 
an accelerated aging-like phenotype in mice [44], 
consistent with a pro-aging effect of the Wnt pathway.  
Drosophila stem cell populations show defects in 
replicative homeostasis during aging in the gut [45, 46] 
and gonads [47-50], however it is currently unknown to 
what extent alterations in stem cell function might limit 
adult  Drosophila life span.  It will be of interest to 
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life span by disrupting the function of one or more stem 
cell populations, and to further explore the role of 
wingless signaling in the maintenance of stem cell 
populations during Drosophila aging. 
 
Over-expression of Ras activated form during 
Drosophila larval development was lethal to males and 
females, and when expressed in adult flies it 
dramatically decreased both male and female life span.  
Ras signaling has been found to shorten life span and 
promote cellular senescence in yeast and mammals [51-
56], whereas in contrast Ras signaling is reported to 
promote longevity in long-lived C. elegans Daf-2 
insulin-like receptor mutants [57].  It will be of interest 
in the future to test in what tissue Ras activated form 
acts to decrease adult fly life span and to determine if 
this might result from an induction of cellular 
senescence. 
 
Over-expression of the caspase inhibitor baculovirus 
p35 in adult flies using the tissue-general Act-GS-255B 
driver had little to no effect on life span, using three 
independent baculovirus p35 transgenes.  In addition, 
over-expression of the caspase inhibitor DIAP1 in 
adults had no consistent effects on life span. While 
caution must be exercised in interpreting a negative 
result, it would tend to suggest that adult fly life span is 
not limited by a canonical caspase-dependent apoptotic 
pathway.  Relevant to this idea, the apoptotic events in 
aging rat skeletal muscle are reported to be relatively 
caspase-independent [6].  When baculovirus p35 was 
expressed during larval development using the tissue-
general Act-GS-255B driver, it caused reduced mean 
life span in the resultant male and female adult flies, 
consistent with the requirement for regulated apoptosis 
in normal fly development.  However, the female adults 
that resulted from tissue-general baculovirus p35 over-
expression during development exhibited an unusual bi-
phasic survival curve that included a subset of adult 
females with increased life span.  This bi-phasic curve 
and subset of long-lived females was not observed with 
nervous-system expression of baculovirus p35 in larvae 
using the Elav-GS driver, suggesting that nervous-tissue 
may not be the critical tissue; however, these expe-
riments were confounded by toxic effect of the Elav-GS 
driver itself in drug-treated larvae. It will be of interest 
in the future to determine what might be the mechanism 
by which baculovirus p35 over-expression in larvae 
produces a subset of females with increased life span, 
and if it might result from the inhibition of apoptosis in 






Drosophila Strains. All the target transgenes for over-
expression (Table 1) were obtained from Bloomington 
Drosophila Stock Center. The ubiquitous Geneswitch 
driver lines Act-GS-255B and Act-GS-255A contain 
multiple copies of a P element construct in which 
expression of the Geneswitch cDNA is under the 
control of the tissue-general Actin5C promoter [16]. The 
UAS-ultraGFP strain contain multiple copies of a UAS-
eGFP construct, and its construction and 
characterization have been recently described [18].  The 
Geneswitch system drivers Elav-GS, MHC-GS, S1-32 
and S1-106 were generously provided by T. Osterwalder 
and R. Davis [19, 20]. 
 
Drosophila Culture.  Drosophila culture and life span 
assays were performed as described previously [16]. 
GeneSwitch virgins were used in the crosses with males 
of other lines, with the exception of strains in which the 
target transgene for over-expression was on the X 
chromosome.  Life span assays consisted of ~25 flies 
per vial, and a total 5 vials for each cohort.  For survival 
assays performed at 25
oC, flies were transferred to new 
vials ever other day. For survival assays preformed at 
29
oC flies were transferred to new vials every other day 
during the first 30-40 days, and then every day for the 
remainder of the life span. RU486 (Mifepristone, 
Sigma) was dissolved in ethanol (100%) to make a 
stock solution of 3.2mg/ml. For adult feeding, 50ul 
RU486 stock solution was added to the surface of each 
vial to produce a final concentration of ~160ug/ml; 50ul 
ethanol was added to the control vials. For larval 
feeding, 0.5ml of 3.2mg/ml RU486 stock solution (or 
the indicated diluted concentration) was added to the 
surface of each bottle to produce a final concentration of 
~160ug/ml (or indicated diluted concentration); 0.5ml 
ethanol was added to control bottles.  
 
GeneSwitch Driver Characterization. Adult flies were 
cultured in vials in the presence and absence of drug for 
two weeks prior to dissection. Adult male and female 
flies, head in half, body in half, midgut and hindgut, 
ovary and testes, were photographed. Larvae at 1
st 
instar, 2
nd instar and 3
rd instar, as well as 3
rd instar 
dissected tissues (brain, midgut and hindgut, salivary 
gland, imaginal discs, and fat body) were also 
photographed. The Leica MZ FLIII fluorescence 
stereomicroscope together with the SPOT software were 
used for photographs: The GFP pictures were taken 
under the fluorescent light with exposure time 4 sec and 
a gain of 2.  
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percent change in mean, percent change in median, and 
log rank p value were calculated using R 2.6.2 [58]. 
Analysis of mortality rate was performed with the 
WinModest statistical package [59]. In the Gompertz-
Makeham model, the increase
 of mortality (µx ) with age 
(x) is expressed as: µx
 = ae
bx+c, where the constant a is 
the initial mortality
  rate,  b is the rate of exponential 
increase in mortality, and c is the age-independent 
mortality.  The age specific mortality rate (µx) was 
calculated using WinModest by binning the days over 
which deaths were counted (since fly deaths were 
recorded every other day) such that µx = (-ln(N x + δx / Nx 
)) / δx  (or  Px = N x + δx / Nx and µx = -1/δx ln(Px )), where 
Nx is the number of flies alive at day x and δx is the bin 
size (2). Parameters (a, b, c) were also calculated based 
on a likelihood ratio test. The full model (ae
bx+c) was 
plotted, and the Gompertz-only component (ae
bx) was 





-µx.  For the decomposed survival curves, 
any value below 0.5% survival was considered to be the 
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St# Genotype  Notes  Abbreviation 
1 w;  GS-Actin255-B;+ 
Ubiquitous GeneSwitch 255B 
Driver 255B 
2 w;  GS-Actin255-A;+ 
Ubiquitous GeneSwitch 255A 
Driver 255A 
3 w;  P{Switch}bun[Switch  1-32];+ 
GeneSwitch Head Fat Body 
Driver S32 
4  w; P{Switch}S1-106 P{Switch}bun[Switch 1-32];+ 
GeneSwitch Head & Thorax-
Abdomen Fat Body Driver  S106 S32 
5  yw; +; GS-Elav  GeneSwitch Elav Driver  Elav 
6  yw; Sp/CyO,FLP.lacZ; MHC:GS  GeneSwitch Muscle Driver 
Sp/CyO, 
MHC 
7  Oregon R ( +; +; +)  wild type   
8  w1118; +; +                                                                        wild type   
9  P{UAS.p35.H}BH3,w*;+;+  UAS-p35 on chromosome 1  p35 
10  w*; P{UAS.p35.H}BH1;+  UAS-p35 on chromosome 2  p35 
11  w*; +; P{UAS.p35.H}BH2  UAS-p35 on chromosome 3  p35 
12  w1118; +; P{UAS-Ras85D.V12}TL1  UAS-Ras85D activated form  Ras act 
13  w*; P{UAS-Ras85D.K}5-1;+ 
 
 
UAS-Ras85D WT form  Ras WT 
14  P{UAS-Ras85D.N17}TL1, w1118; +; +  UAS-Ras85D DN form  Ras DN 
15  w*; P{UAS-wg.H.T:HA1}3C;+ UAS-wg on chromosome 2  wg
a 
16  w*; +; P{UAS-wg.H.T:HA1}6C  UAS-wg on chromosome 3  wg
b 
17 y1  w67c23;  +;P{EPgy2}EY04093  EP-Pk61C  Pk61C
a 
18  w; +; P{EP}Pk61CEP3644/TM6,Tb EP-Pk61C Pk61C
b 
19 w*;  +;  P{UAS-DIAP1.H}3  UAS-DIAP1  DIAP1 
20 y1  w67c23;  P{EPgy2}EY00935  EP-nmo  nmo 
21  y1 w*; +; P{UAS-Egfr.B}32-26-1  UAS-Egfr  Egfr 
22  y1 w67c23; +; P{EPgy2}pntEY03254  EP-pnt  pnt 
23  y1 w67c23; P{EPgy2}Mmp2EY08942/CyO; +  EP-Mmp2  Mmp2 
24  y1 w67c23; +; P{EPgy2}Stat92EEY14209/TM3, Sb1 Ser1  EP-Stat92E  Stat 
25 w*;  +;  P{EPgy2}pucEY09772/TM6C  EP-puc  puc 
26  y1 w67c23; +; P{EPgy2}scramb2EY01180  EP-Sk2  Sk2 
27  y1 w67c23; +; P{EPgy2}EY06207  EP-ban  ban 
28  w1118; +; PBac{WH}CG14544f01091/TM6B, Tb1  XP-CG14544  CG14544 





UAS-p53 point mutation   p53.259H 
 
   



































































































p Value  
 
Exp1 Life span assay using GS255B driver at 29C  
 
8-1 -  w/Y; 255B/+; +  M 115  51.53±8.66 53  ---------  ---------  --------- 
 A  w/Y; 255B/+; +  M 120  47.29±11.06  50  -8.23  -5.66  0.001 
 L w/Y; 255B/+; +  M 40 47.28±12.15  51  -8.26  -3.77  0.002 
 - w/w; 255B/+; +  F 128  54.18±8.26  56  --------- --------- --------- 
 A  w/w; 255B/+; +  F 120  51.74±3.89  52  -4.5  -7.14  4.38E-09 
 L w/w; 255B/+; +  F 120  48.18±8.38  50  -11.07  -10.71  6.30E-11 
12-1 -  w/Y; 255B/+;  Ras act/+  M 122  51.11±11.58  55.5  ---------  ---------  --------- 
 A  w/Y; 255B/+;  Ras act/+  M 128  9.45±3.42  10  -81.5  -81.98  0 
 L w/Y; 255B/+;  Ras act/+  M 0  NA  NA  ---------  ---------  --------- 
 - w/w*; 255B/+;  Ras act/+  F 123  54.19±13.26  59  --------- --------- --------- 
 A  w/w*; 255B/+;  Ras act/+  F 123  12.11±2.8 12  -77.64  -79.66  0 
 L w/w*; 255B/+;  Ras act/+  F 0 NA  NA  --------- --------- --------- 
13-1 -  w/Y; 255B/Ras WT;+  M 124  46.65±9.01 47  ---------  ---------  --------- 
 A  w/Y; 255B/Ras WT;+  M 122  42.3±9.13  42  -9.32  -10.64  1.43E-04 
 L w/Y; 255B/Ras WT;+  M 47 42.06±10.37  43  -9.84  -8.51  0.004 
 - w/w*; 255B/Ras WT;+  F 126  51.31±8.64  52  --------- --------- --------- 
 A  w/w*; 255B/Ras WT;+  F 126  46.84±5.17  46  -8.71  -11.54  8.15E-12 
 L w/w*; 255B/Ras WT;+  F 118  43.66±8.85  46  -14.91  -11.54  0 
1-14 -  Ras DN, w/Y; 255B/+; +  M 127  47.89±9.88 50  ---------  ---------  --------- 
 A  Ras DN, w/Y; 255B/+; +  M 123  43.64±6.87 44  -8.87  -12  5.78E-08 
 L Ras DN, w/Y; 255B/+; +  M 79 44.76±12.49  48  -6.54  -4  0.14 
 - Ras DN, w/w; 255B/+; +  F 121  51.65±14.25  57  --------- --------- --------- 
 A  Ras DN, w/w; 255B/+; +  F 125  51.82±8.3 53  0.32  -7.02  5.09E-04 
 L Ras DN, w/w; 255B/+; +  F 125  45.39±13.16  49  -12.12  -14.04  1.98E-09 
15-1 -  w/Y; 255B/wg
a; +  M 130  52.56±8.37 55  ---------  ---------  --------- 
 A  w/Y; 255B/wg
a; +  M 122  29.83±9.32 32  -43.25  -41.82  0 
 L w/Y; 255B/wg
a; +  M 0  NA  NA  ---------  ---------  --------- 
w/w*; 255B/wg
a; +   -  F 122  55.78±12.01  60  --------- --------- --------- 
 
 
 A  w/w*; 255B/wg
a; +  F 125  33.61±10.55  34  -39.75  -43.33  0 
 L w/w*; 255B/wg
a; +  F 0 NA  NA  --------- --------- --------- 
w/Y; 255B/+;wg
b/+  M 124  52.31±8.81 56  ---------  ---------  ---------  16-1 - 
 A  w/Y; 255B/+;wg
b/+  M 131  45.02±8.04 47  -13.94  -16.07  0 
 L w/Y; 255B/+;wg
b/+  M 0  NA  NA  ---------  ---------  --------- 
w/w*; 255B/+;wg
b/+   -  F 
 
120  51.29±10.38  53  --------- --------- --------- 
 A  w/w*; 255B/+;wg
b/+  F 123  47.55±7.23  49  -7.29  -7.55  3.24E-10 
 L w/w*; 255B/+;wg
b/+  F 0 NA  NA  --------- --------- --------- 
w/Y; 255B/+; Pk61C
a/+  17-1 -  M 122  47.9±9.67  47  ---------  ---------  --------- 
 L w/Y; 255B/+; Pk61C
a/+  M 21 42.81±13.89  47  -10.63  0  0.224 
w/yw; 255B/+; Pk61C
a/+   -  F 127  49.82±16.97  56  --------- --------- --------- 
 L w/yw; 255B/+; Pk61C
a/+  F 121  50.24±11.55  52  0.84  -7.14  8.57E-04 
w/Y; 255B/+; Pk61C
b/+  M 126  57.29±8.23 59  ---------  ---------  ---------  18-1 - 
 L w/Y; 255B/+; Pk61C
b/+  M 24 48.08±10.99  51  -16.06  -13.56  4.11E-12 
w; 255B/+; Pk61C
b/+   -  F 124  54.51±9.89  56.5  --------- --------- --------- 
 L w; 255B/+; Pk61C
b/+  F 121  45.28±13.38  51  -16.93  -9.73  1.79E-14 
w/Y; 255B/+; DIAP1/+  19-1 -  M 120  56.23±8.68 59  ---------  ---------  --------- 
 L w/Y; 255B/+; DIAP1/+  M 93 47.68±17.07  53  -15.22  -10.17  0.002 
w/w*; 255B/+; DIAP1/+   -  F 120  54.64±11.2  57.5  --------- --------- --------- 
 




































































































 L w/w*; 255B/+; DIAP1/+  F 117  46.74±14.76  51  -14.45  -11.3  1.97E-07 
7-1 -  w/Y; 255B/+; +  M 124  52.97±7.68 56  ---------  ---------  --------- 
 A  w/Y; 255B/+; +  M 124  49.73±4.6  50  -6.11  -10.71  6.19E-13 
 L w/Y; 255B/+; +  M 22 44.5±16.86 52  -15.99  -7.14  2.94E-05 
 - w/+; 255B/+; +  F 118  58.39±5.25  59  --------- --------- --------- 
 A  w/+; 255B/+; +  F 122  52.66±4.09  52  -9.81  -11.86  0 
 L w/+; 255B/+; +  F 122  50.45±9.78  53.5  -13.6  -9.32  1.18E-13 
 
Ex 2 Life span assay using GS255B driver at 25C  
 
7-1 -  w/Y; 255B/+; +  M 94 73.17±15.64  78  ---------  ---------  --------- 
 A  w/Y; 255B/+; +  M 93 69.97±12.33  72  -4.38  -7.69  5.22E-04 
 - w/+; 255B/+; +  F 92  87.2±18.44  92  --------- --------- --------- 
 A  w/+; 255B/+; +  F 91  91.93±7.76  94  5.43  2.17  0.940 
20-1 -  w/Y; 255B/+; nmo/+  M 95 66.74±16.11  68  ---------  ---------  --------- 
 A  w/Y; 255B/+; nmo/+  M 90 64.66±14.3 66  -3.12  -2.94  0.102 
 - w/yw; 255B/+; nmo/+  F 97  67.59±28.66  74  --------- --------- --------- 
 A  w/yw; 255B/+; nmo/+  F 95  68.79±30.17  80  1.78  8.11  0.878 
15-1 -  w/Y; 255B/wg
a; +  M 96 72.88±10.31  74  ---------  ---------  --------- 
 A  w/Y; 255B/wg
a; +  M 92 53.14±18.01  56  -27.08  -24.32  0 
 - w/w*; 255B/wg
a; +  F 97  78.89±19.38  84  --------- --------- --------- 
 A  w/w*; 255B/wg
a; +  F 97  53.72±22.13  52  -31.9  -38.1  0 
17-1 -  w/Y; 255B/+; Pk61C
a/+  M 91 64.11±13.4 64  ---------  ---------  --------- 
 A  w/Y; 255B/+; Pk61C
a/+  M 94 62.85±13.08  66  -1.96  3.13  0.555 
 - w/yw; 255B/+; Pk61C
a/+  F 98  70.73±26.23  78  --------- --------- --------- 
 A  w/yw; 255B/+; Pk61C
a/+  F 94  79.81±23.77  90  12.83  15.38  0.149 
21-1 -  w/Y; 255B/+; Egfr/+  M 89 62.38±11.19  66  ---------  ---------  --------- 
 A  w/Y; 255B/+; Egfr/+  M 97 62.06±9.18 64  -0.51  -3.03  0.166 
 - w/y w*; 255B/+; Egfr/+  F 95  65.71±21.16  68  --------- --------- --------- 
 A  w/y w*; 255B/+; Egfr/+  F 100  63.52±17.9  65  -3.33  -4.41  0.076 
19-1 -  w/Y; 255B/+; DIAP1/+  M 102  76.57±13.04  78  ---------  ---------  --------- 
 A  w/Y; 255B/+; DIAP1/+  M 94 73.4±9.53  74  -4.13  -5.13  0.002 
 - w/w*; 255B/+; DIAP1/+  F 98  78.9±18.26  84  --------- --------- --------- 
 A  w/w*; 255B/+; DIAP1/+  F 95  81.39±19.17  88  3.16  4.76  0.011 
22-1 -  w/Y; 255B/+; pnt/+  M 96 62.6±9.74  64 
 
---------  ---------  --------- 
 A  w/Y; 255B/+; pnt/+  M 94 59.15±10.7 60  -5.52  -6.25  0.077 
 - w/yw; 255B/+; pnt/+  F 92  74.32±27.19  85  --------- --------- --------- 
 A  w/yw; 255B/+; pnt/+  F 95  79.77±20.03  88  7.34  3.53  0.402 
 
Exp3 Life span assay using GS255B driver at 25C  
 
7-1 -  w/Y; 255B/+; +  M 100  81.01±15.38  86  ---------  ---------  --------- 
 A  w/Y; 255B/+; +  M 92 80.46±10.42  82  -0.68  -4.65  0.039 
 - w/+; 255B/+; +  F 85  92.49±11.86  94  --------- --------- --------- 
 A  w/+; 255B/+; +  F 99  92.05±13.07  94  -0.48  0  0.571 
13-1 -  w/Y; 255B/Ras WT;+  M 95 75.87±12.26  78  ---------  ---------  --------- 
 A  w/Y; 255B/Ras WT;+  M 98 67.92±14.13  70  -10.48  -10.26  1.62E-06 
 - w/w*; 255B/Ras WT;+  F 96  83.43±12.26  86  --------- --------- --------- 
 A  w/w*; 255B/Ras WT;+  F 98  79.59±10.58  82  -4.6  -4.65  0.001 
23-1 -  w/Y; 255B/Mmp2; +  M 96 69.77±13.03  70  ---------  ---------  --------- 
 A  w/Y; 255B/Mmp2; +  M 96 68.81±10.06  70  -1.37  0  0.117 
 - w/yw; 255B/Mmp2; +  F 98  85.94±18.45  91  --------- --------- --------- 
 A  w/yw; 255B/Mmp2; +  F 101  84.85±18.67  90  -1.27  -1.1  0.109 
24-1 -  w/Y; 255B/+; Stat/+  M 96 64.31±10.06  65  ---------  ---------  --------- 
 A  w/Y; 255B/+; Stat/+  M 99 65.08±13.33  68  1.19  4.62  0.325 
 - w/yw; 255B/+; Stat/+  F 99  70.48±21.48  78  --------- --------- --------- 
 A  w/yw; 255B/+; Stat/+  F 96  62.29±24.99  74  -11.62  -5.13  0.076 
25-1 -  w/Y; 255B/+; puc/+  M 97 70.78±14.98  70  ---------  ---------  --------- 
 A  w/Y; 255B/+; puc/+  M 96 68.96±13.62  68  -2.58  -2.86  0.269 
 



























































































 - w/w*; 255B/+; puc/+  F 84  94.07±15.00  98  --------- --------- --------- 
 A  w/w*; 255B/+; puc/+  F 97  98.1±7.86 100  4.29  2.04  0.135 
 
Exp4 Life span assay using GS255B driver at 25C  
 
7-1 -  w/Y; 255B/+; +  M 92 73.76±18.31  78  ---------  ---------  --------- 
 A  w/Y; 255B/+; +  M 86 71.84±10.87  74  -2.61  -5.13  1.43E-04 
 - w/+; 255B/+; +  F 86  86.28±15.46  90  --------- --------- --------- 
 A  w/+; 255B/+; +  F 101  86.18±10.02  88  -0.12  -2.22  0.035 
26-1 -  w/Y; 255B/+; Sk2/+  M 90 67.22±16.97  72  ---------  ---------  --------- 
 A  w/Y; 255B/+; Sk2/+  M 95 69.85±12.26  72  3.91  0  0.953 
 - w/yw; 255B/+; Sk2/+  F 101  73.29±24.6  84  --------- --------- --------- 
 A  w/yw; 255B/+; Sk2/+  F 106  78.08±19.61  86  6.53  2.38  0.84 
27-1 -  w/Y; 255B/+; ban/+  M 98 66.59±21.91  70  ---------  ---------  --------- 
 A  w/Y; 255B/+; ban/+  M 95 61.56±18.15  62  -7.56  -11.43  0.003 
 - w/yw; 255B/+; ban/+  F 94  76.36±28.78  88  --------- --------- --------- 
 A  w/yw; 255B/+; ban/+  F 96  81.56±18.03  88  6.81  0  0.023 
28-1 -  w/Y; 255B/+;CG14544/+  M 91 75.03±12.8 76  ---------  ---------  --------- 
 A  w/Y; 255B/+;CG14544/+  M 97 77.01±9.82 78  2.64  2.63  0.844 
 - w/w; 255B/+;CG14544/+  F 101  70.99±26.75  82  --------- --------- --------- 
 A  w/w; 255B/+;CG14544/+  F 96  69.33±20.57  79  -2.33  -3.66  2.28E-05 
 
Exp5 Life span assay using GS255B driver, and MHC GS driver at 25C  
 
7-1 -  w/Y; 255B/+; +  M 98 75.06±11.65  79  ---------  ---------  --------- 
 A  w/Y; 255B/+; +  M 97 73.96±12.27  78  -1.47  -1.27  0.161 
 - w/+; 255B/+; +  F 100  87.88±7.74  88  --------- --------- --------- 
 A  w/+; 255B/+; +  F 101  85.33±12.78  88  -2.91  0  0.014 
8-1 -  w/Y; 255B/+; +  M 99 66.55±11.82  68  ---------  ---------  --------- 
 A 
 
w/Y; 255B/+; +  M 97 69.84±10.57  72  4.94  5.88  0.14 
 - w/w; 255B/+; +  F 100  79.6±14.08  84  --------- --------- --------- 
 A  w/w; 255B/+; +  F 97  81.69±3.82  82  2.63  -2.38  0.005 
17-1 -  w/Y; 255B/+; Pk61C
a/+  M 99 64.87±12.41  64  ---------  ---------  --------- 
 A  w/Y; 255B/+; Pk61C
a/+  M 98 62.16±12.33  64  -4.17  0  0.113 
 - w/yw; 255B/+; Pk61C
a/+  F 98  81.96±13.91  86  --------- --------- --------- 
 A  w/yw; 255B/+; Pk61C
a/+  F 99  80.46±11.15  82  -1.82  -4.65  0.001 
18-1 -  w/Y; 255B/+; Pk61C
b/+  M 100  71.2±9.32  74  ---------  ---------  --------- 
 A  w/Y; 255B/+; Pk61C
b/+  M 101  73.33±8.19 74  2.99  0  0.135 
 - w; 255B/+; Pk61C
b/+  F 98  80.27±12.63  82  --------- --------- --------- 
 A  w; 255B/+; Pk61C
b/+  F 100  82.02±4.89  82  2.19  0  0.399 
19-1 -  w/Y; 255B/+; DIAP1/+  M 101  72.97±11.13  76  ---------  ---------  --------- 
 A  w/Y; 255B/+; DIAP1/+  M 101  71.15±11.37  74  -2.5  -2.63  0.425 
 - w/w*; 255B/+; DIAP1/+  F 98  83.02±7.52  84  --------- --------- --------- 
 A  w/w*; 255B/+; DIAP1/+  F 106  79.47±12.78  82  -4.27  -2.38  0.011 
7-6 -  yw/Y;+/CyO; MHC/+  M 96 71.31±13.18  76  ---------  ---------  --------- 
 A  yw/Y;+/CyO; MHC/+  M 98 58.92±12.84  60  -17.38  -21.05  0 
 - yw/+;+/CyO; MHC/+  F 96  78.04±15.76  84  --------- --------- --------- 
 A  yw/+;+/CyO; MHC/+  F 114  52.84±13.75  58  -32.29  -30.95  0 
8-6 -  yw/Y;+/CyO; MHC/+  M 99 56.42±16.69  60  ---------  ---------  --------- 
 A  yw/Y;+/CyO; MHC/+  M 92 43.26±15  48  -23.33  -20  1.61E-12 
 - yw/w;+/CyO; MHC/+  F 93  60.73±18.82  68  --------- --------- --------- 
 A  yw/w;+/CyO; MHC/+  F 99  45.21±13.63  50  -25.55  -26.47  2.22E-16 
17-6 -  yw/Y;+/CyO; MHC/Pk61C
a  M 100  54.32±14.66  58  ---------  ---------  --------- 
 A  yw/Y;+/CyO; MHC/Pk61C
a  M 101  52.46±12.42  56  -3.43  -3.45  0.004 
 - yw;+/CyO; MHC/Pk61C
a  F 100  61.3±19.84  65  --------- --------- --------- 
 A  yw;+/CyO; MHC/Pk61C
a  F 99  39.37±14.22  36  -35.77  -44.62  0 
18-6 -  yw/Y;+/CyO; MHC/Pk61C
b  M 96 56.44±18.89  62  ---------  ---------  --------- 
 A  yw/Y;+/CyO; MHC/Pk61C
b  M 108  53.56±10.21  56  -5.11  -9.68  1.75E-07 
 - yw/w;+/CyO; MHC/Pk61C
b  F 96  55.25±21.21  56  --------- --------- --------- 
 
 




































































































 A  yw/w;+/CyO; MHC/Pk61C
b  F 90  39.42±12.45  38  -28.65  -32.14  1.40E-11 
19-6 -  yw/Y;+/CyO; MHC/DIAP1  M 98 66.71±12.27  68  ---------  ---------  --------- 
 A  yw/Y;+/CyO; MHC/DIAP1  M 98 54.92±10.4 56  -17.68  -17.65  6.66E-15 
 - yw/w*;+/CyO;MHC/DIAP1  F 108  64.89±18.19  71  --------- --------- --------- 
 A  yw/w*;+/CyO;MHC/DIAP1  F 104  57.04±14.85  58  -12.1  -18.31  6.72E-08 
7-6 -  yw/Y;+/Sp; MHC/+  M 99 68.67±13.38  74  ---------  ---------  --------- 
 A  yw/Y;+/Sp; MHC/+  M 98 61.76±12.62  64  -10.07  -13.51  5.34E-08 
 - yw/+;+/Sp; MHC/+  F 94  73.66±13.99  78  --------- --------- --------- 
 A  yw/+;+/Sp; MHC/+  F 102  59.98±8.45  62  -18.57  -20.51  0 
8-6 -  yw/Y;+/Sp; MHC/+  M 96 61.6±14.81 66  ---------  ---------  --------- 
 A  yw/Y;+/Sp; MHC/+  M 94 54.55±15.5 56  -11.45  -15.15  2.47E-06 
 - yw/w;+/Sp; MHC/+  F 93  58.41±17.34  62  --------- --------- --------- 
 A  yw/w;+/Sp; MHC/+  F 102  47.59±12.97  52  -18.53  -16.13  2.70E-14 
17-6 -  yw/Y;+/Sp; MHC/Pk61C
a  M 95 49.31±12.75  54  ---------  ---------  --------- 
 A  yw/Y;+/Sp; MHC/Pk61C
a  M 100  45.14±11.03  48  -8.45  -11.11  1.95E-04 
 - yw;+/Sp; MHC/Pk61C
a  F 99  42.99±20.17  40  --------- --------- --------- 
 A  yw;+/Sp; MHC/Pk61C
a  F 100  35.78±16.13  30  -16.77  -25  0.003 
18-6 -  yw/Y;+/Sp; MHC/Pk61C
b  M 100  56.36±12.56  60  ---------  ---------  --------- 
 A  yw/Y;+/Sp; MHC/Pk61C
b  M 98 51.06±9.77 52  -9.4  -13.33  2.13E-06 
 - yw/w;+/Sp; MHC/Pk61C
b  F 97  56.6±16.25  60  --------- --------- --------- 
 A  yw/w;+/Sp; MHC/Pk61C
b  F 94  41.79±11.81  42  -26.17  -30  1.67E-15 
19-6 -  yw/Y;+/Sp; MHC/DIAP1  M 99 61.21±10.04  62  ---------  ---------  --------- 
 A  yw/Y;+/Sp; MHC/DIAP1  M 97 55.51±9.17 58  -9.32  -6.45  5.02E-08 
 - yw/w*;+/Sp; MHC/DIAP1  F 103  71.13±17.02  78  --------- --------- --------- 
   A  yw/w*;+/Sp; MHC/DIAP1  F 101  62.3±13.23  66  -12.41  -15.38  6.66E-16 
a   Mean life span, days +/- SD. 
 
   














































































































p Value  
 
Exp1 Life span assay of three UAS-p35 lines and UAS-p53.259H with GS255B driver at 25C 
 
7-1 -  w/Y; 255B/+; +  M 120  84.6±14.25 90  ---------  ---------  --------- 
 A  w/Y; 255B/+; +  M  119  83.08±10.94  86  -1.8 -4.44 0.014 
 L  w/Y; 255B/+; +  M 123  78.44±22.48  86  -7.28  -4.44  0.244 
 -  w/+; 255B/+; +  F 116  92.02±9.64  94  --------- ---------  --------- 
 A  w/+; 255B/+; +  F 121  94.69±8.61  94  2.9  0  0.009 
 L  w/+; 255B/+; +  F 124  91.97±15.74  94  -0.05  0  0.047 
1-9 -  p35,w*/Y; 255B/+; +  M 120  68.93±12.49  70  ---------  ---------  --------- 
 A  p35,w*/Y; 255B/+; +  M 123  68.62±11.76  70  -0.45  0  0.681 
 L  p35,w*/Y; 255B/+; +  M 98 33.1±22.91 26  -51.98  -62.86  0 
 -  p35,w*/+; 255B/+; +  F 122  83.28±15.13  86  --------- ---------  --------- 
 A  p35,w*/+; 255B/+; +  F 130  77.15±20.92  82  -7.36  -4.65  0.11 
 L  p35,w*/+; 255B/+; +  F 125  57.52±35.8  70  -30.93  -18.6  0.001 
10-1 -  w/Y; 255B/p35; +  M 117  54.48±13  54  ---------  ---------  --------- 
 A  w/Y; 255B/p35; +  M  121  57.26±8.45  58  5.1 7.41 0.583 
 L  w/Y; 255B/p35; +  M 110  34.25±19.5 34  -37.13  -37.04  5.60E-10 
 -  w/w*; 255B/p35; +  F 120  64.05±14.63  66  --------- ---------  --------- 
 A  w/w*; 255B/p35; +  F 126  60.79±16.68  66  -5.09  0  0.188 
 L  w/w*; 255B/p35; +  F 123  49.37±32.2  54  -22.92  -18.18  0.436 
11-1 -  w/Y; 255B/+; p35/+  M 133  86.03±12.51  90  ---------  ---------  --------- 
 A  w/Y; 255B/+; p35/+  M 122  81.31±13.87  84  -5.49  -6.67  8.92E-06 
 L  w/Y; 255B/+; p35/+  M 56 46.18±24.21  44  -46.32  -51.11  0 
 -  w/w*; 255B/+; p35/+  F 126  87.54±10.04  90  --------- ---------  --------- 
 A  w/w*; 255B/+; p35/+  F 127  82.19±9.91  82  -6.11  -8.89  8.60E-05 
 L  w/w*; 255B/+; p35/+  F 126  64.63±29.62  75  -26.17  -16.67  4.67E-07 
29-1 -  w/Y; 255B/+;p53.259H/+  M 118  71.54±13.86  72  ---------  ---------  --------- 
 A  w/Y; 255B/+;p53.259H/+  M 125  68.90±10.41  70  -3.70  -2.78  0.002 
 L  w/Y; 255B/+;p53.259H/+  M 119  67.73±16.92  70  -5.33  -2.78  0.069 
 -  w; 255B/+; p53.259H/+  F 119  75.40±8.50  76  --------- ---------  --------- 
 A  w; 255B/+; p53.259H/+  F 119  80.66±10.98  82  6.98  7.89  4.05E-08 
 L  w; 255B/+; p53.259H/+  F 125  70.24±22.02  76  -6.84  0  0.202 
 
Exp2 Life span assay of three UAS-p35 lines with head FB driver, whole body FB driver and GS255A driver at 25C 
 
3-7 -  +/Y; S32/+; +  M 75 59.23±14.11  64  ---------  ---------  --------- 
 A  +/Y; S32/+; +  M 63 55.21±15.74  60  -6.79  -6.25  0.013 
 -  w/+; S32/+; +  F 111  59.91±18.96  60  --------- ---------  --------- 
 A  w/+; S32/+; +  F 115  63.77±17.71  66  6.45  10  0.263 
3-9 -  p35,w*/Y; S32/+; +  M 122 
 
62.69±10.62  64  ---------  ---------  --------- 
 A  p35,w*/Y; S32/+; +  M 105  58.3±13.45 60  -6.99  -6.25  0.022 
 -  p35,w*/w; S32/+; +  F 112  59.95±25  72  --------- ---------  --------- 
 A  p35,w*/w; S32/+; +  F 108  59±24.86  68  -1.58  -5.56  0.974 
3-10 -  w*/Y; S32/p35; +  M 123  45.19±7.61 46  ---------  ---------  --------- 
 A  w*/Y; S32/p35; +  M 120  41.52±6.84 42  -8.12  -8.7  1.96E-04 
 -  w*/w; S32/p35; +  F 121  61.62±8.71  62  --------- ---------  --------- 
 A  w*/w; S32/p35; +  F 105  63.28±10.6  66  2.69  6.45  0.036 
3-11 -  w*/Y; S32/+; p35/+  M 125  62.67±12.41  64  ---------  ---------  --------- 
 A  w*/Y; S32/+; p35/+  M 125  60.78±14.07  62  -3.03  -3.13  0.174 
 



























































































 -  w*/w; S32/+; p35/+  F 109  68.44±17.09  74  --------- ---------  --------- 
 A  w*/w; S32/+; p35/+  F 113  70.52±18.12  76  3.04  2.7  0.043 
4-7 -  +/Y;  S106 S32/+; +  M 116  54.12±9.89 56  ---------  ---------  --------- 
 A  +/Y;  S106 S32/+; +  M 118  52.68±9.77 52  -2.67  -7.14  0.208 
 -  w/+; S106 S32/+; +  F 110  58.82±14.95  62  --------- ---------  --------- 
 A  w/+; S106 S32/+; +  F 120  58.07±16.45  63  -1.28  1.61  0.569 
4-9 -  p35,w*/Y; S106 S32/+; +  M 121  47.21±8.48 46  ---------  ---------  --------- 
 A  p35,w*/Y; S106 S32/+; +  M 110  47.67±10.28  48  0.99  4.35  0.263 
 -  p35,w*/w; S106 S32/+; +  F 119  55.18±22.95  66  --------- ---------  --------- 
 A  p35,w*/w; S106 S32/+; +  F 126  47.79±24.9  62  -13.38  -6.06  0.01 
4-10 -  w*/Y; S106 S32/p35; +  M 125  33.39±4.44 34  ---------  ---------  --------- 
 A  w*/Y; S106 S32/p35; +  M 125  32.3±6.16  32  -3.26  -5.88  0.475 
 -  w*/w; S106 S32/p35; +  F 121  49.55±8.14  50  --------- ---------  --------- 
 A  w*/w; S106 S32/p35; +  F 121  50.84±8.85  50  2.6  0  0.107 
4-11 -  w*/Y; S106 S32/+; p35/+  M 125  47.15±6.81 48  ---------  ---------  --------- 
 A  w*/Y; S106 S32/+; p35/+  M 117  48.6±8.42  48  3.07  0  0.072 
 -  w*/w; S106 S32/+; p35/+  F 125  56.81±13.02  60  --------- ---------  --------- 
 A  w*/w; S106 S32/+; p35/+  F 116  60.69±11.7  64  6.83  6.67  0.004 
2-7 -  +/Y; 255A/+; +  M 114  66.04±8.95 67  ---------  ---------  --------- 
 A  +/Y; 255A/+; +  M 117  58.97±15.36  62  -10.69  -7.46  1.48E-05 
 -  w/+; 255A/+; +  F 114  72.65±13.95  78  --------- ---------  --------- 
 A  w/+; 255A/+; +  F 116  75.02±13.19  78  3.26  0  0.064 
2-9 -  p35,w*/Y; 255A/+; +  M 111  65.98±14.65  66  ---------  ---------  --------- 
 A  p35,w*/Y; 255A/+; +  M 115  59.82±13.31  60  -9.34  -9.09  3.78E-05 
 -  p35,w*/w; 255A/+; +  F 113  58.95±20.26  64  --------- ---------  --------- 
 A  p35,w*/w; 255A/+; +  F 117  69.21±17.4  72  17.4  12.5  1.32E-06 
2-10 -  w*/Y;255A/p35; +  M 113  48.98±9.74 48  ---------  ---------  --------- 
 A  w*/Y;255A/p35; +  M 125  47.66±7.19 48  -2.69  0  0.03 
 -  w*/w; 255A/p35; +  F 115  60.57±16.71  66  --------- ---------  --------- 
 A  w*/w; 255A/p35; +  F 118  62±17.79  70  2.35  6.06  0.052 
2-11 -  w*/Y; 255A/+; p35/+  M 115  63.66±11.4 64  ---------  ---------  --------- 
 A  w*/Y; 255A/+; p35/+  M 114  64.92±9.41 64  1.98  0  0.776 
 -  w*/w; 255A/+; p35/+  F 120  67.05±11.58  70  --------- ---------  --------- 
 A  w*/w; 255A/+; p35/+  F 120  68.75±9.08  70  2.54  0  0.41 
 
Exp3  Life span assay of two UAS-p35 lines with whole body FB driver at 29C  
 
7-4 -  w/Y;  S106 S32/+; +  M 124  49.15±12.5 54  ---------  ---------  --------- 
 L  w/Y;  S106 S32/+; +  M 121  49.11±10.75  52  -0.08 
 
-3.7  0.655 
 -  w/+;  S106 S32/+; +  F 121  51.95±10.82  54  --------- ---------  --------- 
 L  w/+;  S106 S32/+; +  F  118  55.29±10.06  60  6.42 11.11 0.029 
8-4 -  w/Y;  S106 S32/+; +  M 121  47.16±10.27  48  ---------  ---------  --------- 
 L  w/Y;  S106 S32/+; +  M 118  42.85±12.89  44  -9.14  -8.33  0.002 
 -  w/w;  S106 S32/+; +  F 124  50.48±11.91  56  --------- ---------  --------- 
 L  w/w;  S106 S32/+; +  F 125  51.63±8.47  54  2.27  -3.57  0.196 
10-4 -  w/Y; S106 S32/p35; +  M 121  50.43±6.73 52  ---------  ---------  --------- 
 L  w/Y; S106 S32/p35; +  M  121  46.5±8.28  48  -7.8 -7.69 4.23E-05 
 -  w*/w; S106 S32/p35; +  F 120  50.4±12.84  56  --------- ---------  --------- 
 L  w*/w; S106 S32/p35; +  F  129  48.57±8.9  50 -3.62 -10.71 1.45E-05 
11-4 -  w/Y; S106 S32/+; p35/+  M 126  44.03±6.5  46  ---------  ---------  --------- 
 L  w/Y; S106 S32/+; p35/+  M 122  41.92±10.42  46  -4.8  0  0.208 
 -  w*/w; S106 S32/+; p35/+  F 122  58.03±6.59  60  --------- ---------  --------- 
 L  w*/w; S106 S32/+; p35/+  F 124  54.81±8.05  56  -5.56  -6.67  8.84E-07 
 
Exp4 Life span assay of two UAS-p35 lines with Elav driver at 29C 
 
7-5 -  yw/Y; +/+; Elav/+  M 131  53.92±7.15 54  ---------  ---------  --------- 
 A  yw/Y; +/+; Elav/+  M 129  52.33±8.14 53  -2.95  -1.85  0.083 
 L  yw/Y; +/+; Elav/+  M 59 35.85±10.58  38  -33.51  -29.63  0 
 
 



























































































 -  yw/+; +/+; Elav/+  F 127  58.15±7.22  60  --------- ---------  --------- 
 A  yw/+; +/+; Elav/+  F 129  57.11±5.19  58  -1.79  -3.33  0.013 
 L  yw/+; +/+; Elav/+  F 120  43.46±7.94  44  -25.26  -26.67  0 
8-5 -  yw/Y; +/+; Elav/+  M 126  44.08±8.36 44.5  ---------  ---------  --------- 
 A  yw/Y; +/+; Elav/+  M 120  43.32±8.76 45  -1.73  1.12  0.186 
 L  yw/Y; +/+; Elav/+  M 102  26.24±8.51 26  -40.48  -41.57  0 
 -  yw/w; +/+; Elav/+  F 124  46.88±9.92  50  --------- ---------  --------- 
 A  yw/w; +/+; Elav/+  F 124  48.13±7.5 49.5  2.67  -1  0.406 
 L  yw/w; +/+; Elav/+  F 114  34.82±10.34  36  -25.73  -28  0 
10-5 -  yw/Y; p35/+; Elav/+  M 125  42.34±6.38 44  ---------  ---------  --------- 
 A  yw/Y; p35/+; Elav/+  M 122  43.34±10.34  46  2.38  4.55  0.007 
 L  yw/Y; p35/+; Elav/+  M 9  20.89±10.3 26  -50.66  -40.91  0 
 -  yw/w*; p35/+; Elav/+  F 121  49±10.63  52  --------- ---------  --------- 
 A  yw/w*; p35/+; Elav/+  F 126  50.16±6.4 51  2.36  -1.92  0.014 
 L  yw/w*; p35/+; Elav/+  F  9  28.22±10.27  32 -42.4 -38.46 1.60E-14 
11-5 -  yw/Y; +; Elav/p35  M 120  51.24±10.46  54  ---------  ---------  --------- 
 A  yw/Y; +; Elav/p35  M 121  48.62±10.1 52  -5.12  -3.7  1.22E-06 
 L  yw/Y; +; Elav/p35  M 1  10±NA  10  -80.48  -81.48  5.60E-10 
 -  yw/w*; +; Elav/p35  F 118  56.77±3.89  58  --------- ---------  --------- 
 A  yw/w*; +; Elav/p35  F 131  52.67±5.08  54  -7.22  -6.9  3.51E-13 
     L  yw/w*; +; Elav/p35  F 0 NA  NA  --------- ---------  --------- 
 
Exp5 Life span assay of two UAS-p35 lines with GS255B driver at 25C  
 
8-1 -  w/Y; 255B/+; +  M 121  62.33±18.12  68  ---------  ---------  --------- 
 L  w/Y; 255B/+; +  M 119  62.57±16.22  68  0.39  0  0.478 
 L1-10  w/Y; 255B/+; +  M 120  66.02±19.38  72  5.91  5.88  7.82E-04 
 -  w/w; 255B/+; +  F 123  75.95±9.37  78  --------- ---------  --------- 
 L  w/w; 255B/+; +  F 124  69.02±12.88  74  -9.13  -5.13  7.69E-07 
 L1-10  w/w; 255B/+; +  F 124  78.18±9.17  80  2.93  2.56  7.84E-04 
10-1 -  w/Y; 255B/p35; +  M 111  56.32±25.51  66  ---------  ---------  --------- 
 L  w/Y; 255B/p35; +  M 4  16±21.6  7  -71.59  -89.39  6.47E-05 
 L1-10  w/Y; 255B/p35; +  M 117  58.56±17.95  62  3.98  -6.06  0.528 
 -  w/w*; 255B/p35; +  F 119  68.47±13.26  72  --------- ---------  --------- 
 L  w/w*; 255B/p35; +  F 30  27.47±16.58  24  -59.89  -66.67  0 
 L1-10  w/w*; 255B/p35; +  F  124  64.5±16.45  70  -5.8 -2.78 0.757 
11-1 -  w/Y; 255B/+; p35/+  M 117  66.15±9.97 68  ---------  ---------  --------- 
 L  w/Y; 255B/+; p35/+  M 1  14±NA  14  -78.84  -79.41  3.38E-14 
 L1-10  w/Y; 255B/+; p35/+  M 123  64.98±15.73  70  -1.78  2.94  0.099 
 -  w/w*; 255B/+; p35/+  F 123  74.41±5.98  76  --------- ---------  --------- 
 L  w/w*; 255B/+; p35/+  F 0 NA  NA  --------- ---------  --------- 
 L1-10  w/w*; 255B/+; p35/+  F 123  74.37±11.95  78  -0.04  2.63  0.003 
 
Exp6 Life span assay of two UAS-p35 lines with Elav driver at 25C 
 
8-5 -  yw/Y; +/+; Elav/+  M 108  61.69±17.95  67  ---------  ---------  --------- 
 L1-10  yw/Y; +/+; Elav/+  M 115  54.17±15.55  58  -12.18  -13.43  1.80E-08 
 -  yw/w; +/+; Elav/+  F 120  57.42±14.79  64  --------- ---------  --------- 
 L1-10  yw/w; +/+; Elav/+  F 117  56.41±10.82  58  -1.75  -9.38  0.004 
10-5 -  yw/Y; p35/+; Elav/+  M 121  46.6±7.2  46  ---------  ---------  --------- 
 L1-10  yw/Y; p35/+; Elav/+  M 115  37.81±9.05 38  -18.86  -17.39  7.06E-14 
 -  yw/w*; p35/+; Elav/+  F 123  50.63±15.32  54  --------- ---------  --------- 
 L1-10  yw/w*; p35/+; Elav/+  F 121  49.19±12.16  50  -2.85  -7.41  0.035 
11-5 -  yw/Y; +; Elav/p35  M 120  54.32±13.04  56  ---------  ---------  --------- 
 L1-10  yw/Y; +; Elav/p35  M  111  52.31±10.98  52  -3.7 -7.14 0.037 
 -  yw/w*; +; Elav/p35  F 123  52.7±13.97  54  --------- ---------  --------- 
   L1-10  yw/w*; +; Elav/p35  F 118  56.63±10.73  58  7.45  7.41  0.091 
a   Mean life span, days +/- SD. 
   
































































  Parameters L  -  chi2 df p  Value  chi2 df p  Value 
Females                 
    one parameter compared at each time       
p35 (X)              Both a and b are constrained 
5.39 x 10
-9  3.96 x 10
-7    a  1.789  1  0.181       
3.89 x 10
-1  3.00 x 10
-1    b  1.516  1  0.218       
2.08 x 10
-2  1.63 x 10
-3    c  59.967 1  57.983 1  <0.001  <0.001 
                 
p35 (2)              b is constrained 
7.71 x 10
-6  2.10 x 10
-4    a  5.234  1  50.203 1  0.022  <0.001 
2.41 x 10
-1  1.92 x 10
-1    b  1.700  1  0.192       
2.52 x 10
-2  1.37 x 10
-3    c  50.610 1  50.154 1  <0.001  <0.001 
                 
p35 (3)              Both a and b are constrained 
3.31 x 10
-6  3.00 x 10
-6    a  0.003  1  0.958       
2.50 x 10
-1  2.46 x 10
-1    b  0.009  1  0.923       
1.36 x 10
-2  1.80 x 10
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